List of Excipients in Branded Drug ACULAR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	ACULAR	ketorolac tromethamine	0023-2181	BENZALKONIUM CHLORIDE
Allergan Inc	ACULAR	ketorolac tromethamine	0023-2181	EDETATE DISODIUM
Allergan Inc	ACULAR	ketorolac tromethamine	0023-2181	HYDROCHLORIC ACID

ACULAR Excipient Strategy and Commercial Opportunities in Ketorolac Ophthalmic Products

Last updated: August 2, 2026

ACULAR is a ketorolac tromethamine ophthalmic solution used for short-term treatment of ocular inflammation and pain, including postoperative cataract symptoms and seasonal allergic conjunctivitis. Its commercial opportunity is no longer based on core active-ingredient exclusivity. The value is in formulation differentiation: preservative-free delivery, improved tolerability, low-volume dosing, multidose packaging, stability, and regulatory positioning.

The principal ACULAR products are 0.5% ketorolac ophthalmic solution, ACULAR LS 0.4%, and preservative-free ketorolac presentations. Their excipient systems are relatively simple, which lowers manufacturing barriers but leaves room for incremental innovation.

What is ACULAR and which formulations are commercially relevant?

ACULAR contains ketorolac tromethamine, a nonsteroidal anti-inflammatory drug administered topically to the eye. The product is available in different strengths and packaging configurations.

Product	Active ingredient	Strength	Primary use	Preservative profile
ACULAR	Ketorolac tromethamine	0.5%	Postoperative ocular inflammation and pain; allergic conjunctivitis	Preserved, generally benzalkonium chloride
ACULAR LS	Ketorolac tromethamine	0.4%	Postoperative ocular inflammation and pain	Preserved
Ketorolac ophthalmic solution, preservative-free	Ketorolac tromethamine	Commonly 0.5%	Ocular inflammation and pain	Preservative-free
Generic ketorolac ophthalmic solutions	Ketorolac tromethamine	0.4% or 0.5%	Same broad indications as reference products	Preserved or preservative-free, depending on product

FDA labeling identifies ketorolac tromethamine as the active ingredient and lists excipients such as sodium chloride, edetate disodium, octoxynol 40, benzalkonium chloride in preserved products, purified water, and pH-adjusting agents [1,2].

What excipients are used in ACULAR ophthalmic products?

The preserved ACULAR formulation uses excipients that support tonicity, chelation, wetting, preservation, and pH control.

Excipient	Formulation function	Commercial and technical relevance
Sodium chloride	Tonicity adjustment	Supports ocular tolerability and osmolality control
Edetate disodium	Chelating agent	Binds metal ions and can improve preservative performance and chemical stability
Octoxynol 40	Surfactant or wetting agent	Supports wetting and dispersion of the formulation on the ocular surface
Benzalkonium chloride	Antimicrobial preservative	Enables multidose packaging but is associated with ocular-surface tolerability concerns
Hydrochloric acid and sodium hydroxide	pH adjustment	Maintains the target pH range
Purified water	Vehicle	Provides the aqueous delivery medium

The formulation strategy is conventional for an aqueous ophthalmic solution. It relies on a water-soluble ketorolac salt rather than a suspension or complex delivery system. That simplicity supports low-cost generic manufacturing and limits the defensibility of the basic formulation.

Why is edetate disodium important in ACULAR?

Edetate disodium has two relevant functions. It can improve preservative activity by reducing the impact of divalent metal ions, and it can help control trace-metal-related degradation pathways. In an ophthalmic product, the excipient also supports a reproducible stability profile during storage.

Its commercial value is greatest in preserved multidose products. A preservative-free product may retain the chelator for stability, but its inclusion must be justified through compatibility, safety, and extractables-and-leachables data.

What role does octoxynol 40 play?

Octoxynol 40 is a nonionic surfactant used to improve wetting and formulation uniformity. In ophthalmic solutions, surfactant concentration must remain tightly controlled because excess surfactant can contribute to ocular irritation.

A reformulator may seek to replace octoxynol 40 with another ophthalmically acceptable surfactant or solubilization aid. The change would require comparative studies covering droplet delivery, surface spreading, preservative effectiveness, assay, impurities, particulate matter, and ocular tolerability.

How does benzalkonium chloride affect ACULAR commercial strategy?

Benzalkonium chloride, commonly called BAK, is the central excipient issue in ACULAR differentiation.

BAK supports multidose sterility after opening, but repeated exposure can damage the ocular surface, particularly in patients with dry eye, pre-existing corneal disease, glaucoma, or prolonged exposure to topical ophthalmic therapy. Cataract patients may receive multiple postoperative drops, increasing the commercial relevance of preservative burden.

This creates two distinct market positions:

1. A low-cost preserved product for routine short-duration use.
2. A preservative-free product for ocular-surface-sensitive patients, high-volume ophthalmology practices, and premium formulary segments.

The excipient strategy should therefore treat BAK as both a manufacturing asset and a commercial limitation.

What formulation patents protect ACULAR?

The original ACULAR formulation and use claims are unlikely to provide meaningful current exclusivity in the United States. Ketorolac ophthalmic products have been marketed for decades, and generic products are available through the abbreviated new drug application pathway.

The current intellectual-property opportunity is more likely to involve incremental claims covering:

• Preservative-free multidose containers.
• Specific low-BAK or alternative-preservative systems.
• Container-closure systems that maintain sterility after repeated use.
• Improved stability of ketorolac in aqueous solution.
• Reduced ocular irritation.
• Controlled droplet size or reduced delivered volume.
• Combination products containing ketorolac and another ophthalmic active.
• Manufacturing methods that reduce degradation products.
• Specific pH, osmolality, chelator, and surfactant ranges.
• Packaging that limits sorption, leachables, or drug loss.

A patent directed only to sodium chloride, edetate disodium, octoxynol 40, BAK, and water would face substantial obviousness and prior-art risk. A stronger patent position would link the excipient system to a measurable technical result, such as improved stability, lower ocular-surface toxicity, preservative-free multidose sterility, or a defined impurity profile.

When does ACULAR lose exclusivity?

Core ACULAR exclusivity has already expired in the United States. The product is exposed to generic competition, and ketorolac ophthalmic solutions are marketed in multiple strengths and presentations.

Exclusivity category	ACULAR position
Small-molecule composition patent	Expired or commercially immaterial
Core ophthalmic formulation exclusivity	Expired or substantially eroded
FDA new chemical entity exclusivity	Expired
Pediatric exclusivity	No current commercial significance
Orange Book patent protection	No meaningful barrier to ordinary generic entry
Current competitive barrier	Brand recognition, physician familiarity, supply reliability, packaging, and differentiated tolerability

The relevant commercial question is no longer whether a generic can enter the active-ingredient market. It is whether a new product can obtain a differentiated formulation, device, or delivery position that supports pricing above standard generic ketorolac.

What is the FDA regulatory status of ACULAR and generic ketorolac?

ACULAR is an FDA-approved prescription ophthalmic product. Generic ketorolac ophthalmic solutions can generally rely on the ANDA pathway when they demonstrate pharmaceutical equivalence and bioequivalence under applicable FDA requirements.

For ophthalmic solutions, the regulatory assessment focuses on more than active-ingredient strength. Key product attributes include:

• Assay and degradation products.
• pH and osmolality.
• Sterility.
• Particulate matter.
• Preservative content.
• Preservative effectiveness.
• Container-closure integrity.
• Delivered dose and drop size.
• Extractables and leachables.
• Stability after opening.
• Compatibility with the dispensing device.

A formulation that changes the preservative, surfactant, chelator, or container system may not qualify as a straightforward generic copy. Depending on the change, the sponsor may pursue an ANDA, a suitability petition, or a 505(b)(2) application. A product with a materially different delivery system or clinical benefit may require a more extensive regulatory package.

What patent litigation and Paragraph IV risks affect ACULAR?

Because the core ACULAR product is mature and generic ketorolac is established, the principal Paragraph IV risk is not directed at the original ACULAR formulation. It would arise if a sponsor introduced a new protected product, such as a preservative-free multidose system, an improved formulation, or a combination product.

A generic applicant challenging a later-listed patent could submit a Paragraph IV certification asserting that the patent is invalid, unenforceable, or not infringed. The commercial consequences depend on:

• Whether the patent is listed in the Orange Book.
• Whether the patent claims the drug, formulation, method of use, or device.
• Whether a 30-month stay is triggered.
• Whether the reference product has meaningful market share.
• Whether the innovator has an authorized generic or settlement strategy.

For a conventional ACULAR equivalent, litigation exposure is relatively limited because generic competition already exists. For a premium preservative-free or device-enabled product, litigation risk would rise if the sponsor builds an Orange Book-listed formulation estate.

What formulations are protected by the strongest ACULAR-related patents?

The most defensible formulation patents would combine composition and performance limitations.

Preservative-free multidose formulations

A preservative-free multidose product is commercially attractive because it addresses BAK exposure while preserving convenience. The patent should focus on the complete system, including:

• A sterile aqueous ketorolac formulation.
• A specific container-closure design.
• A one-way valve or antimicrobial dispensing mechanism.
• Defined microbial ingress performance.
• A validated in-use stability period.
• Controlled droplet volume.

A formulation patent without the device claims may be easier to design around. Device claims without data showing sterility and dose consistency may face enablement and obviousness challenges.

Low-irritation formulations

A sponsor could pursue a formulation with lower surfactant concentration, an alternative wetting agent, adjusted pH, or a reduced preservative load. The strongest evidence would show statistically meaningful improvement in ocular-surface tolerability while maintaining chemical stability and antimicrobial protection.

Combination formulations

Ketorolac combinations with antibiotics, corticosteroids, or other postoperative agents offer a potential commercial extension. The main opportunities are reduced bottle burden and improved adherence. The principal risks are dose compatibility, preservative burden, chemical interaction, and clinical evidence requirements.

How strong is the ACULAR patent estate?

The core patent estate is weak as a barrier to ordinary generic entry. A new formulation estate could be moderate to strong if it protects an integrated formulation and device with demonstrated performance.

Patent strategy	Relative strength	Main vulnerability
Basic ketorolac ophthalmic solution	Low	Extensive prior art and existing generics
BAK-preserved solution with conventional excipients	Low	Routine formulation practice
Preservative-free single-dose unit	Moderate	Design-around through packaging or concentration changes
Preservative-free multidose system	Moderate to strong	Device prior art and sterility evidence
Low-irritation excipient combination	Moderate	Obviousness and weak clinical differentiation
Combination product	Moderate	Clinical, formulation, and regulatory complexity
Manufacturing impurity-control process	Moderate	Narrow claim scope and process replication issues
Device-plus-formulation package	Stronger	Higher development cost and possible non-Orange-Book protection

Which companies compete with ACULAR?

The competitive field includes the original brand, generic manufacturers, and companies selling alternative ophthalmic NSAIDs.

Competitive group	Products or strategy	Commercial position
AbbVie/Allergan legacy portfolio	ACULAR and related ketorolac products	Brand recognition and physician familiarity
Generic manufacturers	Ketorolac tromethamine ophthalmic solutions	Price competition and formulary access
Bausch + Lomb and other ophthalmic companies	Competing postoperative ophthalmic products	Distribution and ophthalmology relationships
NSAID competitors	Nepafenac and bromfenac products	Differentiation through dosing, potency, or positioning
Specialty ophthalmic developers	Preservative-free and device-enabled products	Premium opportunity based on tolerability and convenience

Ketorolac competes with nepafenac and bromfenac in postoperative inflammation and pain. A ketorolac reformulation must therefore show a practical advantage, not merely a different excipient list.

What commercial opportunities exist for ACULAR excipients?

The most attractive opportunities are formulation and packaging extensions rather than new active-ingredient products.

Preservative-free postoperative ketorolac

This is the clearest opportunity. A sponsor could target cataract surgery patients, dry-eye patients, and practices seeking to reduce cumulative BAK exposure. The product could use single-dose vials or a multidose preservative-free dispenser.

Low-volume or low-drip delivery

Reducing drop volume can lower drug waste, improve ocular comfort, and reduce systemic drainage through the nasolacrimal duct. A device that consistently delivers a smaller drop could support device, method-of-use, or combination claims.

Improved multidose packaging

A multidose system that maintains sterility without BAK could command a premium over standard generic bottles. The commercial challenge is the cost of the valve, filling process, sterilization controls, and container-closure validation.

Excipient replacement

Replacing octoxynol 40 or reducing BAK may improve tolerability. The opportunity depends on preserving solubility, stability, preservative performance, and dose uniformity at a commercially acceptable cost.

Combination products

A ketorolac-antibiotic or ketorolac-corticosteroid product could reduce postoperative bottle burden. The regulatory and clinical burden is higher, but the product could compete on adherence and prescribing convenience.

What generic launch scenarios exist for ACULAR?

Standard generic launch

A sponsor markets a conventional 0.4% or 0.5% ketorolac ophthalmic solution using a familiar excipient profile. This is the lowest-cost strategy and has limited pricing power.

Authorized-generic or brand-aligned launch

The brand owner or licensee supplies a generic-equivalent product through a separate label or commercial partner. This protects volume but accelerates price erosion.

Premium preservative-free launch

A sponsor markets preservative-free ketorolac in unit-dose packaging or a multidose preservative-free device. This strategy depends on ophthalmology adoption and payer willingness to reimburse a premium.

505(b)(2) reformulation

A sponsor introduces a materially differentiated formulation or delivery device supported by clinical or comparative data. This can create a new product identity but requires greater investment and may face patent challenges.

What geographic coverage and manufacturing barriers matter?

The United States is a mature generic market. Commercial differentiation is more likely in markets where ophthalmic NSAID competition is fragmented, preservative-free products are underpenetrated, or local procurement rewards supply reliability.

Manufacturing barriers include:

• Sterile aqueous processing.
• Tight control of bioburden and endotoxin.
• Filling of low-volume ophthalmic containers.
• Container-closure integrity testing.
• Compatibility between formulation and dispensing components.
• Control of surfactant and preservative concentration.
• Stability after first opening.
• Extractables and leachables assessment.
• Reliable supply of ophthalmic-grade packaging.

The formulation itself is not difficult to reproduce. The higher barrier is a validated sterile product with a differentiated package and reliable commercial supply.

What revenue exposure does ACULAR create?

ACULAR is a mature product with generic price pressure. Brand revenue is not normally disclosed as a standalone figure, so the commercial assessment should use market share, prescription volume, average selling price, and channel mix rather than historical brand sales alone.

Revenue exposure is highest in:

• Cataract surgery volume.
• Ophthalmology practice formularies.
• Hospital and ambulatory surgery center contracts.
• Preservative-free product uptake.
• Generic tender pricing.
• Supply continuity during manufacturing disruptions.

A conventional generic strategy can generate volume but usually produces limited margin. A preservative-free or device-enabled strategy offers greater pricing potential but requires clinical, regulatory, and manufacturing investment.

Key Takeaways

• ACULAR's core ketorolac ophthalmic formulation has limited remaining exclusivity value.
• Sodium chloride, edetate disodium, octoxynol 40, BAK, pH adjusters, and water form the conventional excipient platform.
• BAK is the main commercial weakness and the clearest reformulation opportunity.
• Preservative-free multidose delivery offers the strongest potential for product differentiation.
• The strongest patent estate would protect the formulation, dispensing device, sterility performance, and delivered dose together.
• Standard ketorolac generics face low patent barriers and intense price competition.
• A premium product needs evidence of improved tolerability, convenience, stability, or adherence.
• Manufacturing complexity is concentrated in sterile filling, packaging, container compatibility, and in-use stability.
• A 505(b)(2) strategy may be appropriate for a materially differentiated formulation or delivery system.
• Competitive products include nepafenac and bromfenac, so formulation differentiation must translate into clinical or commercial value.

FAQs About ACULAR Excipient and Patent Strategy

Is benzalkonium chloride necessary in ACULAR?

BAK is used in preserved ACULAR products to support multidose antimicrobial protection. It is not necessary in single-dose preservative-free packaging, and alternative multidose systems can eliminate or reduce the need for BAK.

Can a company patent a new ACULAR excipient combination?

Yes, but a patent would need more than a routine substitution. The sponsor would need a defensible composition and a technical effect, such as improved stability, reduced irritation, enhanced sterility, or improved delivery performance.

Is preservative-free ketorolac commercially superior to ACULAR?

It can be commercially superior in patients who are sensitive to preservatives or use multiple ophthalmic products. Standard preserved ketorolac generally retains an advantage in manufacturing cost and conventional pharmacy distribution.

Would an ACULAR reformulation require clinical trials?

The requirement depends on the formulation change and regulatory pathway. A conventional generic may rely primarily on pharmaceutical equivalence and product-quality data. A materially different delivery system or clinical claim may require comparative clinical evidence under a 505(b)(2) pathway.

Does ACULAR face biosimilar competition?

No. Ketorolac is a chemically synthesized small molecule, not a biologic. Competitive products are generic drugs, reformulations, and alternative ophthalmic NSAIDs rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2019). ACULAR (ketorolac tromethamine ophthalmic solution) prescribing information.
2. DailyMed. (2024). ACULAR and ketorolac tromethamine ophthalmic solution labeling. National Library of Medicine.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2024). ANDA submissions: Product-specific guidances for generic drug development.
5. U.S. Food and Drug Administration. (2024). Container closure systems for packaging human drugs and biologics. FDA.